Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis

References

• Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816–828.
   PubMed Web of Science ®Google Scholar
• Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European league against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271–2282.
   PubMed Web of Science ®Google Scholar
• Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League against rheumatism/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955–1964.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford). 2004;43(1):49–54.
   PubMed Web of Science ®Google Scholar
• Zampieri S, Valente M, Adami N, et al. Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev. 2010;9(6):449–453.
   PubMed Web of Science ®Google Scholar
• Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14(3):275–285.
   PubMed Web of Science ®Google Scholar
• Gono T, Kuwana M. Inflammatory myopathies: choosing the right biomarkers to predict ILD in myositis. Nat Rev Rheumatol. 2016;12(9):504–506.
   PubMed Web of Science ®Google Scholar
• Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol. 2016;29(5):662–673.
   PubMed Web of Science ®Google Scholar
• Damoiseaux J, Vulsteke JB, Tseng CW, et al. Autoantibodies in idiopathic inflammatory myopathies: clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun Rev. 2019;18(3):293–305.
   PubMed Web of Science ®Google Scholar
• Kuwana M. Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting. J Nippon Med Sch. 2017;84(2):56–63.
   PubMed Web of Science ®Google Scholar
• Targoff IN. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol. 1993;100(1):116S–123S.
   PubMed Web of Science ®Google Scholar
• Tansley SL, McHugh NJ. Myositis specific and associated autoantibodies in the diagnosis and management of juvenile and adult idiopathic inflammatory myopathies. Curr Rheumatol Rep. 2014;16(12):464.
   PubMedGoogle Scholar
• Lam C, Vleugels RA. Management of cutaneous dermatomyositis. Dermatol Ther. 2012;25(2):112–134.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–347.
   PubMed Web of Science ®Google Scholar
• Callen JP. Dermatomyositis. Lancet. 2000;355(9197):53–57.
   PubMed Web of Science ®Google Scholar
• Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006;24(5):363–373.
   PubMed Web of Science ®Google Scholar
• Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2007;46(1):25–28.
   PubMed Web of Science ®Google Scholar
• Ohtsuka T. The relation between nailfold bleeding and capillary microscopic abnormality in patients with connective tissue diseases. Int J Dermatol. 1998;37(1):23–26.
   PubMed Web of Science ®Google Scholar
• Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32(9):1719–1726.
   PubMed Web of Science ®Google Scholar
• Ishigaki K, Maruyama J, Hagino N, et al. Skin ulcer is a predictive and prognostic factor of acute or subacute interstitial lung disease in dermatomyositis. Rheumatol Int. 2013;33(9):2381–2389.
   PubMed Web of Science ®Google Scholar
• Narang NS, Casciola-Rosen L, Li S, et al. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res (Hoboken). 2015;67(5):667–672.
   PubMed Web of Science ®Google Scholar
• Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep. 2011;13(3):175–181.
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626–636.
   PubMed Web of Science ®Google Scholar
• Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25(8):925–933.
   PubMed Web of Science ®Google Scholar
• Satoh M, Tanaka S, Ceribelli A, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017;52(1):1–19.
   PubMed Web of Science ®Google Scholar
• Betteridge Z, Gunawardena H, North J, et al. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 2007;56(9):3132–3137.
   PubMedGoogle Scholar
• Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571–1576.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Hasegawa M, Fujimoto M, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol. 2007;34(5):1012–1018.
   PubMed Web of Science ®Google Scholar
• Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48–55.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 2013;8(4):e60442.
   PubMed Web of Science ®Google Scholar
• Hozumi H, Enomoto N, Kono M, et al. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study. PLoS One. 2015;10(3):e0120313.
   PubMed Web of Science ®Google Scholar
• Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280(1):24–38.
   PubMed Web of Science ®Google Scholar
• Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16(4):R138.
   PubMed Web of Science ®Google Scholar
• Iwata N, Nakaseko H, Kohagura T, et al. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: experience at a single center in Japan. Mod Rheumatol. 2018;29:1–6.
   PubMed Web of Science ®Google Scholar
• Chen Z, Hu W, Wang Y, et al. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis. Clin Rheumatol. 2015;34(9):1627–1631.
   PubMed Web of Science ®Google Scholar
• Moghadam-Kia S, Oddis CV, Sato S, et al. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken). 2016;68(5):689–694.
   PubMed Web of Science ®Google Scholar
• Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51(7):1278–1284.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Takezaki S, Kobayashi I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology (Oxford). 2015;54(5):784–791.
   PubMed Web of Science ®Google Scholar
• Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.
   PubMed Web of Science ®Google Scholar
• González-Moreno J, Raya-Cruz M, Losada-Lopez I, et al. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review. Rheumatol Int. 2018;38(7):1293–1296.
   PubMed Web of Science ®Google Scholar
• Aoyama J, Hayashi H, Yajima C, et al. Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations. Respir Med Case Rep. 2019;26:193–196.
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Ishimoto H, Nakashima S, et al. Clinical features of anti-MDA5 antibody-positive rapidly progressive interstitial lung disease without signs of dermatomyositis. Intern Med. 2019;58(6):837–841.
   PubMed Web of Science ®Google Scholar
• Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49(9):1713–1719.
   PubMed Web of Science ®Google Scholar
• Hozumi H, Fujisawa T, Nakashima R, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91–99.
   PubMed Web of Science ®Google Scholar
• Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49(3):433–440.
   PubMed Web of Science ®Google Scholar
• Fujikawa K, Kawakami A, Kaji K, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol. 2009;38(4):263–267.
   PubMed Web of Science ®Google Scholar
• Chen F, Wang D, Shu X, et al. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int. 2012;32(12):3909–3915.
   PubMed Web of Science ®Google Scholar
• Kang EH, Nakashima R, Mimori T, et al. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord. 2010;11:223.
   PubMed Web of Science ®Google Scholar
• Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken). 2013;65(8):1316–1324.
   PubMed Web of Science ®Google Scholar
• Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65(8):1307–1315.
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res. 2014;2014:290797.
   PubMed Web of Science ®Google Scholar
• Sato S, Murakami A, Kuwajima A, et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One. 2016;11(4):e0154285.
   PubMed Web of Science ®Google Scholar
• Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51(9):1563–1570.
   PubMed Web of Science ®Google Scholar
• Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682–3689.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64(2):513–522.
   PubMed Web of Science ®Google Scholar
• Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223–243.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449–455.
   PubMed Web of Science ®Google Scholar
• Mugii N, Hasegawa M, Matsushita T, et al. Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS One. 2016;11(5):e0154746.
   PubMed Web of Science ®Google Scholar
• Hida A, Yamashita T, Hosono Y, et al. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study. Neurology. 2016;87(3):299–308.
   PubMed Web of Science ®Google Scholar
• Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010;49(9):1726–1733.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147(4):391–398.
   PubMedGoogle Scholar
• Yang H, Peng Q, Yin L, et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther. 2017;19(1):259.
   PubMedGoogle Scholar
• Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985;28(7):796–803.
   PubMedGoogle Scholar
• Komura K, Fujimoto M, Matsushita T, et al. Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci. 2005;40(3):215–217.
   PubMed Web of Science ®Google Scholar
• Espada G, Maldonado Cocco JA, Fertig N, et al. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol. 2009;36(11):2547–2551.
   PubMed Web of Science ®Google Scholar
• Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60(6):1807–1814.
   PubMed Web of Science ®Google Scholar
• Albayda J, Pinal-Fernandez I, Huang W, et al. Dermatomyositis patients with anti-nuclear matrix protein-2 autoantibodies have more edema, more severe muscle disease, and increased malignancy risk. Arthritis Care Res (Hoboken). 2017;69:1771–1776.
   Web of Science ®Google Scholar
• Rogers A, Chung L, Li S, et al. The cutaneous and systemic findings associated with nuclear matrix protein-2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken). 2017;69:1909–1914.
   PubMed Web of Science ®Google Scholar
• Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther. 2012;14(2):R97.
   PubMed Web of Science ®Google Scholar
• Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71(5):710–713.
   PubMed Web of Science ®Google Scholar
• Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford). 2014;53(12):2204–2208.
   PubMed Web of Science ®Google Scholar
• Pachman LM, Khojah AM. Advances in Juvenile dermatomyositis: myositis specific antibodies aid in understanding disease heterogeneity. J Pediatr. 2018;195:16–27.
   PubMed Web of Science ®Google Scholar
• Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep. 2017;7(1):188.
   PubMedGoogle Scholar
• Fujimoto M, Watanabe R, Ishitsuka Y, et al. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28(6):636–644.
   PubMed Web of Science ®Google Scholar
• Gono T, Tanino Y, Nishikawa A, et al. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease. Int J Rheum Dis. 2019;22(8):1582–1586.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015;10:61.
   PubMed Web of Science ®Google Scholar
• Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–721.
   PubMed Web of Science ®Google Scholar
• Kishi T, Rider LG, Pak K, et al. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1*07:01 and severe myositis in Juvenile myositis patients. Arthritis Care Res (Hoboken). 2017;69(7):1088–1094.
   PubMed Web of Science ®Google Scholar
• Stuhlmüller B, Schneider U, González-González JB, et al. Disease specific autoantibodies in idiopathic inflammatory myopathies. Front Neurol. 2019;10:438.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016;87(10):1038–1044.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016;139(Pt 8):2131–2135.
   PubMedGoogle Scholar
• De Lorenzo R, Pinal-Fernandez I, Huang W, et al. Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. Neurology. 2018;90(23):e2068–e2076.
   PubMed Web of Science ®Google Scholar
• Mimori T, Akizuki M, Yamagata H, et al. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest. 1981;68(3):611–620.
   PubMed Web of Science ®Google Scholar
• Mimori T. Clinical significance of anti-Ku autoantibodies–a serologic marker of overlap syndrome? Intern Med. 2002;41(12):1096–1098.
   PubMed Web of Science ®Google Scholar
• Spielmann L, Nespola B, Séverac F, et al. Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes. Ann Rheum Dis. 2019;78(8):1101–1106.
   PubMed Web of Science ®Google Scholar
• Kaji K, Fertig N, Medsger TA, et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken). 2014;66(4):575–584.
   PubMed Web of Science ®Google Scholar
• Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56(9):3125–3131.
   PubMed Web of Science ®Google Scholar
• Sato S, Kuwana M, Fujita T, et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23(3):496–502.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Oddis CV, Goudeau D, et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford). 2016;55(6):991–999.
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Rampudda M, Ekholm L, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford). 2010;49(12):2370–2374.
   PubMed Web of Science ®Google Scholar
• Nakashima R, Imura Y, Hosono Y, et al. The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One. 2014;9(1):e85062.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Murakami A, Kurei S, et al. Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis. J Dermatol Sci. 2016;84(3):272–281.
   PubMed Web of Science ®Google Scholar
• Espinosa-Ortega F, Holmqvist M, Alexanderson H, et al. Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2019;78(6):858–860.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kuwana M, Takehara K. Comparison of anti-OJ antibody detection assays between an immunoprecipitation assay and line blot assay. Mod Rheumatol. 2017;27(3):551–552.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kuwana M, Takehara K. Performance evaluation of a line blot assay system for detection of anti-PM-Scl antibody in Japanese patients with systemic sclerosis. Int J Rheum Dis. 2019;22:1746–1751.
   PubMed Web of Science ®Google Scholar
• Mahler M, Betteridge Z, Bentow C, et al. Comparison of three immunoassays for the detection of myositis specific antibodies. Front Immunol. 2019;10:848.
   PubMed Web of Science ®Google Scholar
• Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96–100.
   PubMed Web of Science ®Google Scholar
• Wang J, Guo G, Chen G, et al. Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol. 2013;169(4):838–847.
   PubMed Web of Science ®Google Scholar
• Kadota H, Gono T, Yamaguchi Y, et al. Initial predictors for mortality in patients with cancer-associated myositis: a multicenter retrospective cohort in japan. Ann Rheum Dis. 2018;77(Suppl2):752.
   PubMedGoogle Scholar
• Sato S, Masui K, Nishina N, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology (Oxford). 2018;57:1212–1221.
   Web of Science ®Google Scholar
• Tsuji H, Nakashima R, Hosono Y, et al. A multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2019. DOI:10.1002/art.41105. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018;57:2114–2119.
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381(3):291–293.
   PubMed Web of Science ®Google Scholar
• Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353(9166):1762–1763.
   PubMed Web of Science ®Google Scholar
• Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52(8):2439–2446.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46(1):124–130.
   PubMed Web of Science ®Google Scholar
• Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48(8):968–971.
   PubMed Web of Science ®Google Scholar
• Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford). 2015;54(8):1420–1428.
   PubMed Web of Science ®Google Scholar
• Kawasumi H, Gono T, Kawaguchi Y, et al. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med. 2015;9(Suppl 1):9–17.
   PubMedGoogle Scholar
• Fafalak RG, Peterson MG, Kagen LJ. Strength in polymyositis and dermatomyositis: best outcome in patients treated early. J Rheumatol. 1994;21(4):643–648.
   PubMed Web of Science ®Google Scholar
• Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94(4):379–387.
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28(10):2230–2237.
   PubMed Web of Science ®Google Scholar
• Carpenter JR, Bunch TW, Engel AG, et al. Surviv al in polymyositis: corticosteroids and risk factors. J Rheumatol. 1977;4(2):207–214.
   PubMed Web of Science ®Google Scholar
• Dankó K, Ponyi A, Constantin T, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004;83(1):35–42.
   PubMed Web of Science ®Google Scholar
• Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore). 1999;78(3):139–147.
   PubMed Web of Science ®Google Scholar
• Schiopu E, Phillips K, MacDonald PM, et al. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. 2012;14(1):R22.
   PubMed Web of Science ®Google Scholar
• Ishizuka M, Watanabe R, Ishii T, et al. Long-term follow-up of 124 patients with polymyositis and dermatomyositis: statistical analysis of prognostic factors. Mod Rheumatol. 2016;26(1):115–120.
   PubMed Web of Science ®Google Scholar
• Moyon Q, Benveniste O. Usefulness of rehabilitation in inflammatory myopathies. Rev Med Interne. 2016;37(11):751–758.
   PubMed Web of Science ®Google Scholar
• Woo TY, Callen JP, Voorhees JJ, et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10(4):592–600.
   PubMed Web of Science ®Google Scholar